Arbutus Biopharma (NASDAQ:ABUS) Given "Buy" Rating at HC Wainwright

Arbutus Biopharma (NASDAQ:ABUS - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They currently have a $5.00 price target on the biopharmaceutical company's stock. HC Wainwright's price objective points to a potential upside of 42.05% from the company's current price.

A number of other equities research analysts have also recently issued reports on ABUS. Chardan Capital increased their target price on shares of Arbutus Biopharma from $4.00 to $4.50 and gave the stock a "buy" rating in a research report on Wednesday, November 6th. JMP Securities boosted their price target on Arbutus Biopharma to $5.00 and gave the company a "buy" rating in a research note on Wednesday, November 6th. StockNews.com upgraded Arbutus Biopharma from a "sell" rating to a "hold" rating in a report on Saturday, August 10th. Finally, Jefferies Financial Group raised their price target on shares of Arbutus Biopharma from $5.00 to $7.00 and gave the company a "buy" rating in a research report on Thursday, September 5th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $5.38.

Arbutus Biopharma Stock Down 3.3 %

Shares of NASDAQ ABUS traded down $0.12 during mid-day trading on Monday, hitting $3.52. 1,063,519 shares of the company traded hands, compared to its average volume of 1,111,173. Arbutus Biopharma has a 1 year low of $1.79 and a 1 year high of $4.72. The business has a 50 day moving average of $3.98 and a two-hundred day moving average of $3.63. The stock has a market capitalization of $667.01 million, a price-to-earnings ratio of -8.47 and a beta of 1.92.

Institutional Investors Weigh In On Arbutus Biopharma

A number of hedge funds and other institutional investors have recently bought and sold shares of ABUS. nVerses Capital LLC purchased a new position in Arbutus Biopharma during the second quarter worth about $34,000. Walleye Trading LLC purchased a new position in Arbutus Biopharma during the 1st quarter worth approximately $36,000. Helen Stephens Group LLC acquired a new stake in shares of Arbutus Biopharma in the third quarter valued at about $50,000. XTX Topco Ltd purchased a new stake in Arbutus Biopharma in the 2nd quarter worth approximately $53,000. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Arbutus Biopharma by 22.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 36,388 shares of the biopharmaceutical company's stock valued at $94,000 after acquiring an additional 6,649 shares during the period. Hedge funds and other institutional investors own 43.79% of the company's stock.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.